Janssen-Silag

Janssen-Silag is the pharmaceutical division of Johnson & Johnson, a leading global healthcare market. Janssen-Silag unites more than 20 thousand people from 57 countries, is one of the most important suppliers of medicines in the global pharmaceutical market, provides 41% of the annual income of the Johnson & Johnson corporation. The company has more than 80 original developments, including haloperidol, domperidone, fentanyl, levamisole, mebendazole, cinnarizine, etc. One of the developments "Janssen-Silag" (neuroleptic risperidone) in 1996 was awarded the international Galen Prize - the highest international award recognizing outstanding achievements in pharmaceuticals. Five Janssen-Silag products are included in the WHO List of Essential Medicines. Today the company is actively developing in a number of therapeutic areas: psychiatry, neurology, oncology, treatment of pain, gastrointestinal and fungal diseases. Janssen-Silag has a good reputation among physicians for its unwavering concern for people's health and quality of life, a commitment to high performance and scientific innovation. Many of the company's products are known in Ukraine, where they have also won the trust of both medical professionals and patients.